Histopathology of prostate tissue after vascular-targeted photodynamic therapy for localized prostate cancer
- PMID: 23948957
- DOI: 10.1007/s00428-013-1454-9
Histopathology of prostate tissue after vascular-targeted photodynamic therapy for localized prostate cancer
Abstract
Low-risk prostate adenocarcinoma is classically managed either with active surveillance or radical therapy (such as external radiotherapy or radical prostatectomy), but both have significant side effects. Vascular-targeted photodynamic therapy (VTP) is a focal therapy proposed as an alternative approach for localized, low-volume, and low-Gleason score (≤6) carcinomas. We report histological modifications observed in prostate biopsies of 56 patients, performed 6 months after VTP using the photosensitizer TOOKAD® Soluble (WST11) and low-energy laser administered in the tumor area transperineally by optic fibers. In 53 patients, we observed sharply demarcated hyaline fibrotic scars, with or without rare atrophic glands, sometimes reduced to corpora amylacea surrounded by giant multinuclear macrophages. Mild chronic inflammation, hemosiderin, and coagulative necrosis were also observed. When residual cancer was present in a treated lobe (17 patients), it was always located outside the scar, most often close to the prostate capsule, and it showed no therapy-related modification. Histopathological interpretation of post-WST11 VTP prostate biopsies was straightforward, in contrast with that of prostate biopsies after radio or hormonal therapy, which introduces lesions difficult to interpret. VTP resulted in complete ablation of cancer in the targeted area.
Similar articles
-
Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy.BJU Int. 2015 Dec;116(6):888-96. doi: 10.1111/bju.12816. Epub 2015 Apr 21. BJU Int. 2015. PMID: 24841929 Clinical Trial.
-
TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.BJU Int. 2013 Oct;112(6):766-74. doi: 10.1111/bju.12265. BJU Int. 2013. PMID: 24028764 Clinical Trial.
-
Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials).Eur Urol Focus. 2019 Nov;5(6):1022-1028. doi: 10.1016/j.euf.2018.04.003. Epub 2018 Apr 13. Eur Urol Focus. 2019. PMID: 29661587 Clinical Trial.
-
Treatment of localized prostate cancer using WST-09 and WST-11 mediated vascular targeted photodynamic therapy-A review.Photodiagnosis Photodyn Ther. 2015 Dec;12(4):567-74. doi: 10.1016/j.pdpdt.2015.10.001. Epub 2015 Oct 20. Photodiagnosis Photodyn Ther. 2015. PMID: 26467273 Review.
-
[Vascular targeted photodynamic therapy in low-risk prostate cancer. A literature review].Prog Urol. 2019 Jul-Aug;29(8-9):393-401. doi: 10.1016/j.purol.2019.05.004. Epub 2019 Jun 29. Prog Urol. 2019. PMID: 31266699 Review. French.
Cited by
-
Real-Time and Delayed Imaging of Tissue and Effects of Prostate Tissue Ablation.Curr Urol Rep. 2023 Oct;24(10):477-489. doi: 10.1007/s11934-023-01175-4. Epub 2023 Jul 8. Curr Urol Rep. 2023. PMID: 37421582 Review.
-
Trial watch: an update of clinical advances in photodynamic therapy and its immunoadjuvant properties for cancer treatment.Oncoimmunology. 2023 Jun 18;12(1):2226535. doi: 10.1080/2162402X.2023.2226535. eCollection 2023. Oncoimmunology. 2023. PMID: 37346450 Free PMC article.
-
Final Results of a Phase I Trial of WST-11 (TOOKAD Soluble) Vascular-targeted Photodynamic Therapy for Upper Tract Urothelial Carcinoma.J Urol. 2023 May;209(5):863-871. doi: 10.1097/JU.0000000000003202. Epub 2023 Feb 1. J Urol. 2023. PMID: 36724067 Clinical Trial.
-
Photodynamic therapy for prostate cancer: Recent advances, challenges and opportunities.Front Oncol. 2022 Sep 23;12:980239. doi: 10.3389/fonc.2022.980239. eCollection 2022. Front Oncol. 2022. PMID: 36212416 Free PMC article. Review.
-
Vascular and Collagen Target: A Rational Approach to Hypertrophic Scar Management.Adv Wound Care (New Rochelle). 2023 Jan;12(1):38-55. doi: 10.1089/wound.2020.1348. Epub 2021 Aug 10. Adv Wound Care (New Rochelle). 2023. PMID: 34328823 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
